Drugs / Epidolex
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05351801 Comparator | Jun 2023 → Sep 2028 expected | neuropathy, painful | VA Office of Research and Development | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epidolex | “Participants will receive a target dose of 800 mg per day of CBD (Epidolex).” NCT05351801 ↗ |
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05351801 ↗ |